KDR and neoplasm: At the different postinjection time points, the PE-conjugated anti-VEGFR2 antibody of the dual-targeted NBs showed relatively stronger and larger range of fluorescence signals compared to the FITC-conjugated anti-HER2 antibody, indicating that the dual-targeted acoustic contrast agent was more easily to targetedly accumulate on the surface of tumor vessel endothelial cells.